These molecular interactions and furthermore their varying expression over time between first diagnosis and progression, metastases or recurrence, after acquiring therapy resistance or during treatment have demonstrated the dynamics of PD-L1 in multiple tumor entities (Gadiot et al., 2011; Darb-Esfahani et al., 2016; Han et al., 2016; Ock et al., 2017). Here, CD274 is linked to neoplasm.